1. XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers.
XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers. Tumors from RIP-Tag2 mice treated for 3 weeks, from age 14 to 17 weeks, with anti-VEGF antibody (A) or XL184 (B). Confocal microscopic images showing tumor cells (insulin, red) and acinar cells (amylase, green) after anti-VEGF antibody (A) or XL184 (B); arrows mark islands of acinar cells surrounded by tumor cells (A). Scattered tumor cells infiltrate the exocrine pancreas after anti-VEGF antibody (C) but not XL184 (D). Irregular tumor-cell shape after anti-VEGF antibody compared to rounded shape after XL184 (E, F, arrows). Contrasting effects of vehicle, anti-VEGF antibody, and XL184 on Invasion index (G) and trapped-amylase cells after treatment from age 14 to 17 weeks (H). Western blot showing mesenchymal markers in tumors after the 3 treatments from age 14 to 15 weeks (I). Contrasting levels of E-cadherin immunoreactivity (red, arrows) in tumors after the 3 treatments from age 14 to 17 weeks (J-L). *P < 0.05 vs. vehicle; #P < 0.05 vs. anti-VEGF antibody; 4–5 mice/group. Scale bar in panel L applies to all images: 150 μm for A and B; 25 μm for C and D; 60 μm for E and F; 45 μm for J–L.
Barbara Sennino et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research